Raymond James Financial
KPTI icon

Raymond James Financial’s Karyopharm Therapeutics KPTI Stock Holding History

Raymond James Financial’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-90
Closed -$388 – 5892
2025
Q2 		$388 Buy
+90
New +$442 ﹤0.01% 6701

Other funds holding KPTI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Raymond James Financial's KPTI Position: Q3 2025 in Review

Raymond James Financial sold out of Karyopharm Therapeutics (KPTI) in Q3 2025, closing a stake of 90 shares — an estimated $388 sold.

Raymond James Financial first reported a position in KPTI in Q2 2025 and held it in 1 quarter. The position peaked at $388 in Q2 2025. 52 funds tracked by Wall St. Rank hold KPTI as of Q3 2025.

  • Raymond James Financial reported no remaining Karyopharm Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 90 Karyopharm Therapeutics shares in Q3 2025, an estimated $388.
  • Raymond James Financial first reported a position in Karyopharm Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Karyopharm Therapeutics position peaked at $388 in Q2 2025.
  • 52 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.